Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, misleading investors with false claims of cognitive improvement and selective data reporting. read more
SEC Charges Cassava Sciences Over Manipulated Alzheimer’s Trial Data, Company And Former Execs Agree To Pay Penalty